Friday, December 8, 2023
Thailand PR News
  • Banking
  • Companies
  • Economy
  • Press Releases
    • PR Newswire
  • Tech
No Result
View All Result
Thailand Business PR
  • Banking
  • Companies
  • Economy
  • Press Releases
    • PR Newswire
  • Tech
Friday, December 8, 2023
No Result
View All Result
Thailand Business PR
No Result
View All Result

Innovative Breakthrough: Taiwan-BioActive Lipid (T-BAL) Redefines the Functional Food Landscape with Lipid Nanoparticles

CISION PRNewswire by CISION PRNewswire
November 21, 2023
in Press Release, Tech
Reading Time: 4 mins read
A A
AZ Asia-Pacific partners with Green Radar to enhance its email security offerings across ASEAN
Share on FacebookShare on Twitter

TAICHUNG, Nov. 21, 2023 /PRNewswire/ — In a groundbreaking stride within the functional food domain, Taiwan’s Lipid Encapsulation and Analysis Corporation has harnessed the potential of Lipid Encapsulated Technology to unveil a revolutionary product line. Introducing nano-sized spheres adept at carrying natural compounds, these groundbreaking nanoparticles are set to reshape the health-centric culinary landscape, particularly within the burgeoning realm of functional plant-based meats.

At the forefront of this transformative breakthrough stands Taiwan-BioActive Lipid (T-BAL)( https://www.t-bal.com ), a company committed to pioneering lipid research. Specializing in Lipid Encapsulation Technology, T-BAL epitomizes expertise in lipid analysis and manufacturing. The company has launched a paradigm-shifting product line, leveraging advanced knowledge in lipidomics to craft nanoparticles capable of transporting an assortment of lipids, including phospholipids, ceramides, and neutral lipids.

T-BAL’s dedication to lipid research transcends conventional boundaries, evident in their proficiency to analyze and manipulate an extensive spectrum of lipids. Profoundly versed in the significance of phospholipids as fundamental building blocks of cell membranes, the essential role of ceramides in skin health, and the vital role of neutral lipids containing fatty acids and bioactive compounds, T-BAL excels in the intricate world of lipidomics.

Delving into lipidomics, a discipline comprehensively analyzing the structure and function of lipids, T-BAL boasts a portfolio encompassing over 4000 different lipids. This trailblazing approach demonstrates a steadfast commitment to pushing the boundaries of achievable results in lipid research.

RelatedPosts

FPT IS to receive first patent in US

Whole Exome Sequencing Advancements in Unraveling Rare Diseases in Japan

Bitget Leads Industry with Solid Proof of Reserves Ratio of 171%

TOPPAN LEEFUNG IS NOW TOPPAN NEXT

In a departure from conventional supplements available in pill form, T-BAL‘s creations predominantly take the form of lipid particle into foods, blurring the lines between traditional supplements and functional food products. This innovative approach falls under the category of "nutriceutics," a concept derived from nutritional pharmacology.

Acknowledging the stagnation in the market due to the dominance of traditional functional beverages, T-BAL‘s team draws upon extensive biomedical research to propose a game-changing strategy. Leveraging years of expertise in lipidomics, the team transforms their findings into the realm of "nutriceutics." The United Nations predicts that the global population of individuals aged 65 and above will reach 2 billion by 2050.

Responding to this demographic shift, the team develops a novel nutritional ingredient, Lipid Encapsulated Particles, serving as a carrier for functional natural remedies. This breakthrough extends beyond supplements, introducing a format that combines the benefits of "functional meat" with a carrier for health-enhancing ingredients. Addressing the need for a paradigm shift, this innovative approach provides consumers with a novel and convenient way to integrate health-promoting compounds into their diet.

Scaling up production challenges the prevailing norm, where similar products are predominantly available in beverage form. T-BAL‘s Lipid Encapsulated Particles are set to redefine the landscape of functional ingredients in the market, offering a unique carrier for a variety of health-enhancing compounds. This groundbreaking development aligns with the company’s commitment to providing solutions that cater to the evolving needs of consumers.

Beyond Lipid Encapsulated Particles, the company introduces a range of health supplements and foods using the new brand name "Life Dr" ( https://www.lifedr.com.tw ). Notable offerings include the BEETROOT Vitality Drink, enriched with patented beetroot extract; the Elderberry High-C Tablet, featuring a high concentration of Vitamin C and elderberry extract, registered and approved by Taiwan’s Food and Drug Administration; and the Spicy Popcorn using the brandname Guo Xiao Fu, a low-sugar and low-oil snack enhanced with Italy’s indena patented phytosome technology for green tea extract, creating a unique blend that promotes calorie burning.

T-BAL‘s foray into the realm of functional foods is poised to reshape the market. Offering consumers a diverse range of products that seamlessly marry culinary innovation with health-conscious choices, this pioneering company stands at the forefront of providing solutions that not only meet evolving dietary preferences but also address the increasing demand for products promoting overall well-being.

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
Tags: PRNewswire
Previous Post

Lufax Holding Ltd Announces Plan to Implement ADS Ratio Change

Next Post

Trip.com Group Limited Reports Unaudited Third Quarter of 2023 Financial Results

CISION PRNewswire

CISION PRNewswire

Related Posts

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

PharmaBlock Officially Joins United Nations Global Compact

December 8, 2023
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma

December 8, 2023
iQIYI's Chief Content Officer at Asia TV Forum: Driving Premium Chinese Content to Global Prominence

iQIYI's Chief Content Officer at Asia TV Forum: Driving Premium Chinese Content to Global Prominence

December 8, 2023
Next Post
SS&C Completes Acquisition of Iress' Managed Funds Administration Business

Trip.com Group Limited Reports Unaudited Third Quarter of 2023 Financial Results

Most Popular

  • ‘Central Retail’ shares vision for ONE APEC, strengthening the private sector and driving the future...

    ‘Central Retail’ shares vision for ONE APEC, strengthening the private sector and driving the future…

    3 shares
    Share 1 Tweet 1
  • Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of NABOTA

    2 shares
    Share 1 Tweet 1
  • Thai exports started to show signs of recovery in August. SCB EIC foresees a reversal towards expansion in 2024

    2 shares
    Share 1 Tweet 1
  • Strong Vehicle Production Outlook Boosts Indonesia’s Overall RRI

    2 shares
    Share 1 Tweet 1
  • Stable outlook for APAC sovereigns as growth rebounds and debt stabilizes

    2 shares
    Share 1 Tweet 1

Subscribe via Email

Enter your email address to subscribe and receive notifications of new posts by email.

  • Thailand PR News
  • News
  • My account
  • Privacy Policy
  • Cart
  • Contact Us
  • Submit a PR News
  • 泰国公关新闻
  • ไทย
  • English
  • 中文 (中国)

© 2022 Siam News Network - Thailand Business News and advertising Network. Powered by VLoss.

No Result
View All Result
  • Banking
  • Companies
  • Economy
  • Press Releases
    • PR Newswire
  • Tech

© 2022 Siam News Network - Thailand Business News and advertising Network. Powered by VLoss.